Event context and recent share performance

Rhythm Pharmaceuticals (RYTM) has drawn investor attention after recent trading, with the stock closing at US$84.39 and showing a 2% decline over the past day and a 19.5% decline over the past 3 months.

The recent 3 month share price return of negative 19.5% contrasts with a 1 year total shareholder return of 41.7% and a 3 year total shareholder return around 4.4x. This suggests short term momentum has faded while longer term holders remain ahead.

If Rhythm’s recent pullback has you rethinking your portfolio mix, this could be a good moment to look at other rare disease and obesity treatment peers using the 31 healthcare AI stocks.

With Rhythm trading at US$84.39 and sitting at a large discount to one set of analyst price targets and an estimated intrinsic value, you might ask yourself whether this is a genuine opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 38.5% Undervalued

With Rhythm’s fair value narrative sitting at $137.27 against a last close of $84.39, the current gap reflects a very different story to the recent share pullback.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years. Extension of intellectual property protection to 2034 for the lead asset and to 2040+ for next generation compounds, along with orphan drug exclusivity incentives in the U.S. and EU, create a multi year window of strong pricing power and high net margins, protecting earnings from generic/biosimilar erosion.

Curious what kind of revenue ramp, margin shift, and valuation multiple are baked into that fair value number? The narrative leans on bold growth, profitability and capital structure assumptions that are anything but conservative.

Result: Fair Value of $137.27 (UNDERVALUED)

However, the story can shift quickly if ongoing net losses and heavy spending persist, or if setmelanotide faces regulatory or competitive setbacks that limit uptake.

Another way to look at Rhythm’s value

So far the story has leaned heavily on future cash flows and analyst fair value. Yet on simple sales based metrics, Rhythm looks expensive, with a P/S ratio of 30.4x versus a peer average of 6.9x and a fair ratio of 17.2x that the market could move toward. That kind of gap can add valuation risk even when growth expectations look strong. How comfortable are you with paying such a premium for every dollar of revenue?

Next Steps

If this mix of optimism and caution leaves you undecided, quickly review the full picture and weigh the company's 3 key rewards.

Looking for more investment ideas?

If Rhythm is only one piece of your watchlist, widen your options now so you do not miss other opportunities that might suit your style and goals.

• Spot underappreciated opportunities early by scanning screener containing 23 high quality undiscovered gems before other investors catch on.
• Strengthen your core holdings by focusing on companies in the solid balance sheet and fundamentals stocks screener (41 results) that pair financial resilience with fundamental support.
• Calm your nerves in volatile markets by filtering for the 72 resilient stocks with low risk scores that score well on stability and risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.